We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sinovac Biotech Ltd | NASDAQ:SVA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.47 | 6.47 | 6.00 | 0 | 00:00:00 |
From Jan 2020 to Jan 2025
DOW JONES NEWSWIRES
Sinovac Biotech Ltd. (SVA) announced it has been selected as one of four companies to supply seasonal-influenza vaccines to the Beijing Public Health Bureau.
Shares jumped about 21% premarket to $7.08 recently. The stock has more than quadrupled this year.
Some 2.8 million city residents will receive free innoculations to prevent and control both seasonal flu and the H1N1 virus, said Sinovac.
The company has been among the vaccine providers in the past. "We are confident of our flexibility to be able to fill large seasonal flu vaccine orders while also executing the [research and development] and large-scale production of our H1N1 vaccine," said Chairman and Chief Executive Weidong Yin.
That vaccine, the company said last week, was shown to be safe.
-By Kevin Kingsbury, Dow Jones Newswires; 212-416-2354; kevin.kingsbury@dowjones.com
1 Year Sinovac Biotech Chart |
1 Month Sinovac Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
